• About
• Links
• Contact
• Sitemap

Global Tuberculosis Strategies

The importance, danger and costs of tuberculosis in the 21st century cannot be understated or underestimated. Though nearly extinct in the 20th century, over 1.6 billion people worldwide suffer from tuberculosis, and it is now presenting a major crisis in public health circles.

As illustrated by Kenneth G. Krul, Phd., in Kalorama Information's Global Tuberculosis Strategies, there are abundant opportunities for diagnostic and pharmaceutical companies in combating the global tuberculosis threat. As the author details, there are primarily three focal points for the development of strategy for combating tuberculosis: potential market, epidemiology (tuberculosis patient trends) and technology, and Krul reviews how diagnostic and pharmaceutical companies can incorporate these focal points into strategy.

Lack of proper diagnosis is one of the barriers to tuberculosis treatment. Krul goes into detail about screening techniques and the potential market for diagnostic products. In addition, treatment markets are defined for major regions of the world.

Kalorama Information's Global Tuberculosis Strategies, authored by Kalorama Information analyst Kenneth G. Krul, PhD, covers these points in detail and presents the most authoritative look at the global tuberculosis threat, strategies to combat tuberculosis, and the market opportunities that can be created in tuberculosis treatment. As part of its coverage, the report includes:

• Extensive Tuberculosis Etiology necessary to understand this unique disease.
• Epidemiologic Statistics including 30 Tables of Incidence, Prevalence and Mortality Statistics by Country, by Region and by Type of Tuberculosis.
• Theoretical Market Sizes for Screening/Diagnosis as well as Treatment by Region and by Type of Tuberculosis (MDR and non-MDR).
• Complete overview of Tuberculosis Screening Procedures.
• Review of Products used for treatment of Tuberculosis.
• A Glossary of Important Terms.

A truly global round-up, the report focuses in detail on the following regions:

• Africa
• The Americas
• Eastern Mediterranean
• Europe
• Southeast Asia
• Western Pacific

Marketing directors, product managers, sales managers and business development executives in both diagnostic and pharmaceutical companies will benefit from this unique resource.

Table of Contents

CHAPTER ONE: Executive Summary

• Market Potential
• Epidemiology
• Technology
• Scope and Methodology

CHAPTER TWO: The Basics of TuberculosiS

• Tuberculosis  Fundamentals
  • Etiology and Pathogenesis
  • Etiology
  • Pathogenesis
  • Primary Infection
  • Secondary/Disseminated Tuberculosis
• Tuberculosis  Epidemiology
  • General  Epidemiology
  • Molecular Epidemiology

CHAPTER THREE: Tuberculosis Screening and DiagnosiS

• Overview
• Skin Testing
• Laboratory Testing
  • Adenosine Deaminas
  • Nucleic Acid Amplification Tests (NAAT)/Molecular Diagnostics
  • Interferon-
  • Microbiological Studies
  • Culture - vs - Non-Culture Testing
  • Culture-Based Systems
  • Non-Culture Methods
  • Nucleic Acid Amplification (NAA)
  • Diagnostic development must be based on assessment of medical needs.
  • Specifications must be defined.
  • The tests should be designed to be used where the patients are.
  • There is insufficient knowledge about local conditions:
  • High-tech strategies should not be force-fit to low-tech settings:
  • Simplification is needed in the interim:
  • Fundamental research questions must be addressed.
  • Public leadership is required in priority setting:
  • Access and pricing issues must be clarified.

CHAPTER FOUR: Tuberculosis  Therapeutics

• Tuberculosis Drugs: First Line
  • Isoniazid (INH)
  • Rifampin (RIF)
  • Ethambutol (EMB)
  • Pyrazinamide (PZA)
• Tuberculosis Drugs: Second Line
  • Aminoglycosides
  • Fluoroquinolones
  • Polypeptides
  • Thioamides
  • Cycloserine
  • p-Aminosalicylic Acid
  • Other Drugs
• Management of Relapse, Treatment Failure, and Drug Resistance
  • Treatment of Tuberculosis in HIV/AIDS Patients
  • Multi-Drug Resistance in Tuberculosis
  • Therapeutic Progress

CHAPTER FIVE: Strategic Assessment of Tuberculosis

• Market Potential
  • Global Tuberculosis Strategies
  • United States Agency for International Development (USAID)
  • The Stop TB Partnership
  • Global Drug Facility (GDF)

APPENDIX: Glossary  

 

table of exhibits

 

CHAPTER ONE: Executive Summary

• Table 1-1: Estimated Theoretical Total Global Market Potentials for TuberculosisTesting & Therapeutics Products by Region, 2005 (Millions)
• Figure 1-1: Theoretical Distribution of Global Tuberculosis Therapeutics andTesting Products Markets : 2005
• Figure 1-2: Theoretical Distribution of the Total Global Tuberculosis Testing Products Markets: 2005 
• Figure 1-3: Theoretical Distribution of the Total Global Tuberculosis TherapeuticsMarkets: 2005
• Table 1-2: Global Tuberculosis Incidence by Region: 2005
• Table 1-3: Global Tuberculosis Prevalence by Region: 2005
• Table 1-4: Global Tuberculosis Mortality by Region : 2005

CHAPTER TWO: The Basics of Tuberculosis

• Table 2-1: Global Tuberculosis Incidence by Region: 2005
• Table 2-2: Tuberculosis Incidence in High-Burden Countries: 2005
• Figure 2-1: Global Tuberculosis Incidence Rates by Region: 2005 (Cases per 100,000 Population per Year)
• Figure 2-2: Global Tuberculosis Incidence Distribution by Region: 2005
• Figure 2-3: Global Tuberculosis Incidence Distribution versus Population Distribution by Region: 2005
• Figure 2-4: Global Tuberculosis Incidence Rates by Region: 1990 - vs - 2005 (Cases per 100,000 Population per Year)
• Table 2-3: Global Tuberculosis Prevalence by Region: 2005
• Table 2-4: Tuberculosis Prevalence in High-Burden Countries: 2005
• Table 2-4: Tuberculosis Prevalence in High-Burden Countries: 2005
• Figure 2-5: Global Tuberculosis Prevalence Rates by Region: 2005 (Cases per 100,000 Population per Year)
• Figure 2-6: Global Tuberculosis Prevalence Distribution by Region: 2005
• Figure 2-7: Global Tuberculosis Prevalence Distribution versus Population Distribution by Region: 2005          
• Figure 2-8: Global Tuberculosis Prevalence Rates by Region: 1990 - vs - 2005 (Cases per 100,000 Population per Year)
• Table 2-5: Global Tuberculosis Mortality by Region(Africa, Americas, Eastern Mediterranean, Europe, Southeast Asia, Western Pacific), 2005
• Table 2-6: Tuberculosis Mortality in High-Burden Countries: 2005
• Figure 2-9: Global Tuberculosis Mortality Rates by Region: 2005
• Figure 2-10: Global Tuberculosis Mortality Distribution by Region: 2005
• Figure 2-11: Global Tuberculosis Mortality Distribution versus Population Distribution by Region: 2005           
• Figure 2-12: Global Tuberculosis Mortality Rates by Region: 1990 - vs - 2005
• Figure 2-13: Comparison of Tuberculosis Incidence, Prevalence and Mortality by Region: 2005 
• Figure 2-14: Comparison of Tuberculosis Incidence, Prevalence and MortalityRates by Region, 2005
• Table 2-7: Global HIV-Associated Tuberculosis Incidence by Region: 2005
• Figure 2-15: Global HIV-Associated Tuberculosis Incidence Ratesby Region: 2005
• Figure 2-16: Global HIV-Associated Tuberculosis Incidence Distribution by Region: 2005         
• Table 2-8: Global HIV-Associated Tuberculosis Prevalence by Region(Africa, Americas, Eastern Mediterranean, Europe, Southeast Asia, Western Pacific): 2005
• Figure 2-17: Global HIV-Associated Tuberculosis Prevalence Ratesby Region, 2005 (Cases per 100,000 Population per Year
• Figure 2-18: Global HIV-Associated Tuberculosis Prevalence Distributionby Region, 2005
• Table 2-9: Global HIV-Associated Tuberculosis Mortality by Region (Africa,Americas, Eastern Mediterranean, Europe, Southeast Asia, WesternPacific), 200
• Figure 2-19: Global HIV-Associated Tuberculosis Mortality Rates by Region: 2005 (Deaths per 100,000 Population per Year
• Figure 2-20: Global HIV-Associated Tuberculosis Mortality Distribution by Region: 200

CHAPTER THREE: Tuberculosis Screening and Diagnosi

• Table 3-1: USDHHS Classification System for Tuberculosi
• Table 3-2: CDC Classification System for Tuberculosis in Refugees and Immigrants
• Table 3-3: Molecular Diagnostic Assay Products for the Diagnosis ofTuberculosis and Tuberculosis-Like Condition
• Table 3-4: Rapid Culture-Based Diagnostic and DST Product
• Table 3-5: Phage-Based Tests
• Tale 3-6: Manufacturers and Tuberculosis Tests Reviewed by WHO
• Table 3-7: Antigen-Based Tuberculosis Diagnosis Tests
• Table 3-8: Nucleic Aid Amplification Tests for Tuberculosis Diagnosis
• Table 3-9: Other Non-Culture Tests for Tuberculosis Diagnosis

CHAPTER FOUR: Tuberculosis  Therapeutics

• Table 4-1: Rating System for the Strength of Treatment Recommendations Basedon Quality of Evidence
• Table 4-2: General Regimen for the Dosing of First-Line Antituberculosis Drugs
• Table 4-3: Drug Regimens for Culture-Positive Pulmonary Tuberculosis Caused by Drug-Susceptible Organisms
• Table 4-4: General Regimen for the Dosing of  Second-Line Antituberculosis Drugs
• Table 4-5: Number and Percentage of MDR-TB and XDR-TB Cases byGeographic Region: 2000 - 2004
• Table 4-6: New Therapeutics for Tuberculosis in Development

CHAPTER FIVE: Strategic Assessment of Tuberculosis

• Figure 5-1: Theoretical Distribution of Global Tuberculosis Therapeutics andTesting Products Markets: 2005
• Figure 5-2: Theoretical Distribution of the Total Global Tuberculosis TestingProducts Markets: 2005
• Figure 5-3: Theoretical Distribution of Global Tuberculosis Testing Products Markets for Screening: 2005
• Figure 5-4: Theoretical Distribution of Global Tuberculosis Testing Products Markets for Diagnosis/Susceptibility Testing: 2005
• Table 5-2: Estimated Theoretical Total Global Market Potentials forTuberculosis Testing Products: 2005 (Millions)
• Figure 5-5: Theoretical Distribution of the Total Global TuberculosisTherapeutics Markets: 2005
• Figure 5-6: Theoretical Distribution of Global Non-MDR TuberculosisTherapeutics Markets: 2005
• Figure 5-7: Theoretical Distribution of Global MDR/XDR TuberculosisTherapeutics: 2005
• Table 5-3: Estimated Theoretical Total Global Market Potentials for Tuberculosis Therapeutics: 2005
• Figure 5-8: Realistic Distribution of Global Tuberculosis Therapeutics and Testing Products Markets: 2005
• Table 5-4: Estimated Realistic Global Market Potentials for TuberculosisTherapeutics and Testing Products: 2005
• Figure 5-9: Realistic Distribution of the Total Global Tuberculosis TestingProducts Markets: 2005
• Figure 5-10: Realistic Distribution of Global Tuberculosis Testing Products Markets for Screening, 2005
• Figure 5-11: Realistic Distribution of Global Tuberculosis Testing Products Markets for Diagnosis/Susceptibility Testing: 2005
• Table 5-5: Estimated Realistic Total Global Market Potentials for TuberculosisTesting Products: 2005
• Figure 5-12: Realistic Distribution of the Total Global Tuberculosis TherapeuticsMarkets, 2005
• Figure 5-13: Realistic Distribution of Global Non-MDR TuberculosisTherapeutics Markets: 2005
• Figure 5-14: Realistic Distribution of Global MDR/XDR TuberculosisTherapeutics: 2005
• Table 5-6: Estimated Realistic Total Global Market Potentials for TuberculosisTherapeutics: 2005

 

Other users found this report page using the following search terms: Tuberculosis tubercle bacillus strategies tuberculosis tb global treatment used termstuberculosis market ethambutol glossary

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.